ALS
109
21
25
49
Key Insights
Highlights
Success Rate
77% trial completion
Published Results
19 trials with published results (17%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 72/100
13.8%
15 terminated out of 109 trials
76.6%
-10.0% vs benchmark
6%
7 trials in Phase 3/4
39%
19 of 49 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 49 completed trials
Clinical Trials (109)
Multicenter ALS Imaging Study
Multimodal Tracking of Therapy Activity and Effort During Rehabilitation
Healey ALS MyMatch Common Screening Protocol
Extension Study Following the Studies MT-1186-A03 or A04 to Evaluate the Safety of Oral Edaravone in Subjects With ALS
Safety Study of Oral Edaravone Administered in Subjects With ALS
Efficacy and Safety Study of Oral Edaravone Administered in Subjects With ALS
A Study of TCD601 (Siplizumab) in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients
Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS)
The BANYAN Trial, an ALS MyMatch Trial Evaluating Safety, Biomarker Activity, and Microglial Activation of Nasal Foralumab
PET Imaging of Cyclooxygenases in Neurodegenerative Brain Disease
Radicava® (Edaravone) Findings in Biomarkers From ALS (REFINE-ALS)
Digital Tools for Assessment of Motor Functions and Falls in ALS
Neurologic Stem Cell Treatment Study
Feasibility of the BrainGate2 Neural Interface System in Persons With Tetraplegia (BG-Tablet-01)
Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS
ALS/MND Natural History Study Data Repository
INdependence Through Endovascular Neuroprosthetic Technology (INTENT): an Early Feasibility Study
ECoG BMI for Motor and Speech Control
Functional Outcomes and Control Using Synchron BCI - Canada
AMX0114 in Adult Participants With Amyotrophic Lateral Sclerosis